Description

Global Opioid-Induced Constipation Treatment Market

 

Global Opioid Induced Constipation Treatment Market are the drugs used for its pain relieving properties in non-cancer and chronic pain. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Furthermore, long-term use of opioids cause harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard tools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite.

 

The Opioid-Induced Constipation Treatment Marketgrowing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global Opioid-Induced Constipation Treatment Market. Furthermore, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the Opioid-Induced Constipation Treatment Market over the forecast period. However, lack of awareness regarding opioid induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the opioid-induced constipation treatment market.

 

Opioid-Induced Constipation Treatment Market

Opioid-Induced Constipation Treatment Market

 

The Global opioid-induced constipation treatment market is segmented on the basis of drug type, formulation type, route of administration, and distribution channel

 

Based on drug type, opioid induced constipation treatment market has been segmented into the following

  • Peripherally restricted μ-opioid receptor antagonists
  • Non-selective opioid antagonists
  • μ -opioid receptor antagonists
  • Locally acting chloride channel activators

 

Based on formulation type, opioid induced constipation treatment market has been segmented into the following

  • Solids
  • Semi-solids
  • Liquids

 

Based on route of administration, Opioid-Induced Constipation Treatment Market has been segmented into the following

  • Oral
  • Parenteral (Subcutaneous Injection)

 

Based on distribution channel, opioid-induced constipation treatment market has been segmented into the following

  • Drugstore
  • Retail pharmacies
  • Hospital pharmacies

 

The Global Opioid Induced Constipation Treatment Market is in the growing stage, several players are actively engaged in the development of the opioid induced constipation treatment market products. Major acquisitions and collaborations among companies to commercialize opioid-induced constipation treatment market products to drive the market growth. For instance, in March 2015, the co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi Sankyo, and in October 2014, the entry of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioid-induced constipation treatment market. Launching of new products, approval of new drugs from various regulatory bodies, and pipeline products under clinical trials are the key factors fuelling the growth of the opioid-induced constipation treatment market. For instance, Linaclotide was approved by the FDA in August 2012 and by the European Medicines Agency for the treatment in adults with constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

 

Geographically, Global Opioid Induced Constipation Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in the opioid-induced constipation treatment market followed by Europe and Asia-Pacific. North America holds the largest share due to expanding the base of opioid-induced constipation patients, According to the American Society of Interventional Pain Physician, in 2013, the U.S. alone was responsible for nearly 80% of the global consumption of opioids. Europe accounts for the significant share in the opioid-induced constipation treatment market owing to increased demand for opioid analgesics in various European countries such as UK, France, Spain, Germany etc. However, growing elderly population in India and China, and rise in healthcare spending are creating the huge growth opportunity for the players in Asia-Pacific region. Apart from that, Latin America and the Middle East are the potential areas for the growth of opioid-induced constipation treatment market because of the increase in opioid-induced constipation sufferers.

 

Some of the players in the market are GlaxoSmithKline plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG (U.K.), AIKO Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), Valeant Pharmaceuticals International Inc. (Canada), Abbott Laboratories (U.S.), Purdue Pharma LP (U.S.) Shionogi Inc. (U.S.) and Cosmo Pharmaceuticals  N.V. (Ireland) to name a few.

 

  • In March 2017, FDA approved Symphonic (Naldemedine) for the treatment of Opioid-Induced Constipation, which was manufactured by Purdue Pharma LP and Shionogi

 

  • In March 2016, AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (Naloxegol) in the European Union (EU)

 

Report Outline:

 

  • The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario


Location

GEOGRAPHY

PBI Location Map

1. Executive summary
 
2. Global Opioid-Induced Constipation Treatment Market Introduction
2.1. Global Opioid-Induced Constipation Treatment Market – Taxonomy
2.2. Global Opioid-Induced Constipation Treatment Market –Definitions
2.2.1. Type of vaccine
2.2.2. End User
 
3. Global Opioid-Induced Constipation Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Opioid-Induced Constipation Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Opioid-Induced Constipation Treatment Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Opioid-Induced Constipation Treatment Market – Product Innovations
 
4. Global Opioid-Induced Constipation Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
 
5. Global Opioid-Induced Constipation Treatment Market, By Drug Type, 2013 – 2017 and Forecast, 2018 – 2024
5.1. Peripherally restricted μ-opioid receptor antagonists
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Non-selective opioid antagonists
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. μ -opioid receptor antagonists
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
 
6. Global Opioid-Induced Constipation Treatment Market Forecast, By Formulation Type, 2013 – 2017 and Forecast, 2018 – 2024
6.1. Solids
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Semi-Solids
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Liquids
6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
 
7. Global Opioid-Induced Constipation Treatment Market Forecast, By Route of administration , 2013 – 2017 and Forecast, 2018 – 2024
7.1. Oral
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
 
8. Global Opioid-Induced Constipation Treatment Market Forecast, By Distribution Channel , 2013 – 2017 and Forecast, 2018 – 2024
8.1. Drug Stores
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Hospital Pharmacies
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
 
9. Global Opioid-Induced Constipation Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
9.1. North America
9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.5.3. Market Opportunity Analysis
9.6. Global Opioid-Induced Constipation Treatment Market – Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2018 – 2024
 
10. North America Opioid-Induced Constipation Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
10.1.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Peripherally restricted μ-opioid receptor antagonists
10.1.1.2. Non-selective opioid antagonists
10.1.1.3. μ -opioid receptor antagonists
10.1.1.4. Locally acting chloride channel activators
10.1.2. Formulation Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Solids
10.1.2.2. Semi-Solids
10.1.2.3. Liquids
10.1.3. Route of administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Oral
10.1.3.2. Parenteral
10.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Drugstore
10.1.4.2. Retail pharmacies
10.1.4.3. Hospital pharmacies
10.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.1.6. North America Opioid-Induced Constipation Treatment Market – Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2018 – 2024
10.1.7. North America Opioid-Induced Constipation Treatment Market Dynamics – Trends
 
11. Europe Opioid-Induced Constipation Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
11.1.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Peripherally restricted μ-opioid receptor antagonists
11.1.1.2. Non-selective opioid antagonists
11.1.1.3. μ -opioid receptor antagonists
11.1.1.4. Locally acting chloride channel activators
11.1.2. Formulation Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Solids
11.1.2.2. Semi-Solids
11.1.2.3. Liquids
11.1.3. Route of administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Oral
11.1.3.2. Parenteral
11.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Drugstore
11.1.4.2. Retail pharmacies
11.1.4.3. Hospital pharmacies
11.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Spain
11.1.5.5. Italy
11.1.5.6. Russia
11.1.5.7. Poland
11.1.5.8. Rest of Europe
11.1.6. Europe Opioid-Induced Constipation Treatment Market – Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2018 – 2024
11.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics – Trends
 
12. Asia-Pacific Opioid-Induced Constipation Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
12.1.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Peripherally restricted μ-opioid receptor antagonists
12.1.1.2. Non-selective opioid antagonists
12.1.1.3. μ -opioid receptor antagonists
12.1.1.4. Locally acting chloride channel activators
12.1.2. Formulation Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Solids
12.1.2.2. Semi-Solids
12.1.2.3. Liquids
12.1.3. Route of administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Oral
12.1.3.2. Parenteral
12.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Drugstore
12.1.4.2. Retail pharmacies
12.1.4.3. Hospital pharmacies
12.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of Asia-Pacific
12.1.6. Asia-Pacific Opioid-Induced Constipation Treatment Market – Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2018 – 2024
12.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics – Trends
 
13. Latin America Opioid-Induced Constipation Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
13.1.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Peripherally restricted μ-opioid receptor antagonists
13.1.1.2. Non-selective opioid antagonists
13.1.1.3. μ -opioid receptor antagonists
13.1.1.4. Locally acting chloride channel activators
13.1.2. Formulation Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Solids
13.1.2.2. Semi-Solids
13.1.2.3. Liquids
13.1.3. Route of administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Oral
13.1.3.2. Parenteral
13.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Drugstore
13.1.4.2. Retail pharmacies
13.1.4.3. Hospital pharmacies
13.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Opioid-Induced Constipation Treatment Market – Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2018 – 2024
13.1.7. Latin America Opioid-Induced Constipation Treatment Market Dynamics – Trends
 
14. Middle East and Africa Opioid-Induced Constipation Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
14.1.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1.1. Peripherally restricted μ-opioid receptor antagonists
14.1.1.2. Non-selective opioid antagonists
14.1.1.3. μ -opioid receptor antagonists
14.1.1.4. Locally acting chloride channel activators
14.1.2. Formulation Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.2.1. Solids
14.1.2.2. Semi-Solids
14.1.2.3. Liquids
14.1.3. Route of administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.3.1. Oral
14.1.3.2. Parenteral
14.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.4.1. Drugstore
14.1.4.2. Retail pharmacies
14.1.4.3. Hospital pharmacies
14.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. MEA Opioid-Induced Constipation Treatment Market – Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2018 – 2024
14.1.7. MEA Opioid-Induced Constipation Treatment Market Dynamics – Trends
 
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. GlaxoSmithKline plc (U.K.)
15.2.2. AstraZeneca U.K)
15.2.3. Pfizer Inc. (U.S.)
15.2.4. SLA Pharma AG (U.K.)
15.2.5. AIKO Biotechnology, Inc. (U.S.)
15.2.6. Cubist Pharmaceuticals (Merck & Co. Inc.,) (U.S.)
15.2.7. Takeda Pharmaceutical Company Limited (Japan)
15.2.8. Boehringer Ingelheim GmbH (Germany)
15.2.9. Bayer AG (Germany)
15.2.10. Valeant (Canada)
15.2.11. Abbott Laboratories (U.S.)
15.2.12. Purdue Pharma LP (U.S.)
15.2.13. Shionogi Inc. (U.S.)
15.2.14. Cosmo Pharmaceuticals N.V. (Ireland)
 
16. Research Methodology
 
17. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX